5 Stocks Pushing The Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 4 points (0.0%) at 15,449 as of Wednesday, Feb. 5, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 771 issues advancing vs. 2,156 declining with 142 unchanged.

The Drugs industry currently sits down 1.6% versus the S&P 500, which is down 0.4%. On the negative front, top decliners within the industry include Grifols ( GRFS), down 4.6%, Regeneron Pharmaceuticals ( REGN), down 2.0% and Valeant Pharmaceuticals International ( VRX), down 1.6%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. Actavis ( ACT) is one of the companies pushing the Drugs industry lower today. As of noon trading, Actavis is down $2.60 (-1.4%) to $182.46 on average volume. Thus far, 639,566 shares of Actavis exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $180.70-$185.50 after having opened the day at $185.18 as compared to the previous trading day's close of $185.06.

Actavis plc, an integrated specialty pharmaceutical company, develops, manufactures, markets, and distributes pharmaceutical products in the United States, Canada, and internationally. Actavis has a market cap of $31.7 billion and is part of the health care sector. Shares are up 10.2% year-to-date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Actavis a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Actavis as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full Actavis Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

4. As of noon trading, Bristol-Myers Squibb Company ( BMY) is down $0.48 (-1.0%) to $48.46 on average volume. Thus far, 4.8 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 8.2 million shares. The stock has ranged in price between $47.52-$49.00 after having opened the day at $48.52 as compared to the previous trading day's close of $48.94.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $80.1 billion and is part of the health care sector. Shares are down 7.9% year-to-date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 6 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

3. As of noon trading, Biogen Idec ( BIIB) is down $7.35 (-2.4%) to $300.83 on average volume. Thus far, 833,600 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $294.02-$307.39 after having opened the day at $307.39 as compared to the previous trading day's close of $308.18.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $71.0 billion and is part of the health care sector. Shares are up 7.5% year-to-date as of the close of trading on Tuesday. Currently there are 14 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Biogen Idec Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Pfizer ( PFE) is down $0.38 (-1.2%) to $30.80 on average volume. Thus far, 16.6 million shares of Pfizer exchanged hands as compared to its average daily volume of 25.6 million shares. The stock has ranged in price between $30.58-$31.18 after having opened the day at $30.99 as compared to the previous trading day's close of $31.18.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $198.3 billion and is part of the health care sector. Shares are up 2.6% year-to-date as of the close of trading on Tuesday. Currently there are 7 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pfizer Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Gilead ( GILD) is down $3.18 (-3.9%) to $78.84 on heavy volume. Thus far, 13.7 million shares of Gilead exchanged hands as compared to its average daily volume of 11.0 million shares. The stock has ranged in price between $76.71-$82.00 after having opened the day at $81.98 as compared to the previous trading day's close of $82.02.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $120.9 billion and is part of the health care sector. Shares are up 9.2% year-to-date as of the close of trading on Tuesday. Currently there are 18 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Gilead Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%